DDInter1934 DDInter1676
Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug administration). Vilanterol was designed based on the salmeterol molecular scaffold, particularly as a antedrug analog of salmeterol modification by modifying the salmeterol molecule to create homochiral compounds with the (R)-configuration. Vilanterol is 1000 and 400 fold more selective for β2 than β1 and β3 adrenoceptors, respectively, with a faster onset of action than salmeterol. Additionally, vilanterol demonstrated a significantly longer duration of action than salmeterol, with the bronchodilator effect still apparent at 22h. Vilanterol
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Vilanterol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dexamethasone
Vilanterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Azithromycin
Vilanterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin degludec
Vilanterol {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Vilanterol {u} may lead to a major life threatening interaction when taken with {v} Carvedilol
Vilanterol may cause a minor interaction that can limit clinical effects when taken with Dexamethasone
Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Azithromycin
Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Vilanterol may lead to a major life threatening interaction when taken with Macimorelin
Vilanterol may lead to a major life threatening interaction when taken with Carvedilol